Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-10
SponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

About this trial

This is a multicenter, parallel-group, open-label, randomized controlled, superiority interventional clinical study initiated by investigators from Shanghai General Hospital (Study Protocol No.: IT-CRU-FAMB-001, Version V1.1, dated December 29, 2025), with Wang Xiaojuan as the principal investigator and the Department of Ophthalmology as the responsible department, collaborating with The First Affiliated Hospital of Zhengzhou University and Yantai Yuhuangding Hospital as participating centers. Launched on October 1, 2025, and scheduled to complete on April 1, 2027, the study aims to evaluate the efficacy of the Dynamic Spatiotemporal Optical Film (S.T.O.P®KIT) in retarding axial length growth in children with low hyperopia (primary endpoint) and compare the change in spherical equivalent power measured by autorefractometer under cycloplegia between the experimental and control groups (secondary endpoint). A total of 180 eligible children aged 6-10 years with low hyperopia will be randomly divided into the experimental group (90 cases) and the control group (90 cases) at a 1:1 ratio using simple randomization. The experimental group will receive two pairs of customized plano-spherical and plano-cylindrical glasses with S.T.O.P optical films of different phases (replaced at 6 months) and undergo follow-up every 3 months for 12 months, while the control group will only receive regular ophthalmic re-examinations without active intervention (with free dynamic optical films and customized glasses provided upon completion of all follow-ups). The study will adopt Analysis of Covariance (ANCOVA) for statistical analysis, with strict data management and quality control measures in place to ensure data authenticity and reliability, and will comply with the Declaration of Helsinki, Chinese GCP, and relevant ethical requirements to protect the safety, rights, and interests of study participants.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Eligible study participants must meet all the following criteria: 1. Age: 6-10 years old;

+0.75D ≤ Spherical equivalent power ≤ +3.00D;

Anisometropia ≤ 1.50D;

Astigmatism ≤ 1.50D;

Disqualifiers

Patients with strabismus;

Patients with abnormal stereopsis;

Comorbidity with other ophthalmic diseases, including developmental abnormalities affecting visual function and refractive status;

Previous ocular surgery history;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Attaching different phase Dynamic Spatiotemporal Optical Films (S.T.O.P® KIT) when wearing spectacle frames

    Device

    1. First, two pairs of eyeglasses need to be fitted, with S.T.O.P optical films of different phases attached regularly; 2. Follow-up visits are conducted every 3 months, and eyeglasses are replaced at 6 months (with changes in S.T.O.P optical film design and phase); 3. All lenses are plano-spherical and plano-cylindrical lenses (0D sphere, 0D cylinder); 4. Monitoring of axial length, visual acuity, and corresponding ophthalmic examinations are performed.

Treatment groups

180 Participants
are divided into 2 treatment groups
Group A: Experimental GroupExperimental treatment 1 intervention
Group B: Control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Difference in the change in axial length

Difference in the change in axial length from baseline to 12 months after eyeglass fitting between the experimental group and the control group.

Time frame
Baseline, 3-month, 6-month, 9-month and 12-month

Secondary outcomes

1

Difference in the change in spherical equivalent power

Difference in the change in spherical equivalent power measured by autorefractometer under cycloplegia from baseline to 12 months after eyeglass fitting between the experimental group and the control group.

Time frame
Baseline, 3-month, 6-month, 9-month and 12-month

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: